Gaiqing Wang | Neurodegeneration Disease | Research and Development Excellence Award

Posted on by ScienceFather

Prof. Gaiqing Wang | Neurodegeneration Disease | Research and Development Excellence Award

Prof. Gaiqing Wang, Sanya Central Hospital (The Third People’s Hospital of Hainan Province), China

Prof. Gaiqing Wang is a distinguished neurologist affiliated with Sanya Central Hospital, Hainan Province, specializing in cerebrovascular diseases. Holding a Ph.D. from Central South University, he focuses on cerebral small vessel disease and endogenous waste clearance in the brain. With over 70 publications, including 27 SCI-indexed papers, Prof. Wang investigates mechanisms of intracerebral hemorrhage and neurodegenerative disorders. He leads numerous research projects funded by national and provincial bodies, exploring innovative therapeutic approaches. His contributions extend to consultancy, industry projects, and authoring books and patents. A member of prestigious professional societies, his work bridges neuroscience research with clinical applications 🧠🔬.

Publication profile

Orcid

Academic and Professional Background 🎓

Gaiqing Wang, currently serving as a Professor at Sanya Central Hospital, earned a Ph.D. in Neurology from Central South University in 2006. Specializing in cerebral small vessel disease and brain waste clearance mechanisms, Wang has authored over 70 papers and secured funding for 13 research projects. His impactful contributions include elucidating the role of microglia in hematoma clearance post-intracerebral hemorrhage and exploring circadian regulation of brain clearance systems. Wang’s academic prowess is underscored by leadership in consultancy projects and publication of several books and patents, consolidating his standing as a distinguished figure in neurological research.

Research Focus

Gaiqing Wang primarily focuses on neuroinflammation and neuroprotection in various neurological disorders, prominently in conditions like Alzheimer’s disease, intracerebral hemorrhage, and subarachnoid hemorrhage. His research explores mechanisms involving oxidative stress, microglial activation, and therapeutic interventions such as dexmedetomidine and PPAR-γ agonists. Wang’s work spans across multiple facets of brain injury and repair, emphasizing the roles of microglia, astrocytes, and clearance systems in these pathological processes. His contributions highlight the intricate signaling pathways and potential therapeutic targets 🧠🔬, advancing understanding and treatment strategies for severe neurological conditions.

Publication Top Notes

Dexmedetomidine mitigates neuroinflammation in an Alzheimer’s disease mouse model via the miR-204-3p/FBXL7 signaling axis

Published in Brain Research (2024)
Year of Publication: 2024 🧠
Neuroprotection by Nrf2 via modulating microglial phenotype and phagocytosis after intracerebral hemorrhage

Published in Heliyon (2023)
Year of Publication: 2023 🧠
Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders

Published in Neurobiology of Disease (2023)
Year of Publication: 2023 🧠
Clearance Systems in the Brain, From Structure to Function

Published in Frontiers in Cellular Neuroscience (2022)
Year of Publication: 2022 🧠
Editorial: Brain injury and repair following cerebrovascular diseases: From bench to bedside

Published in Frontiers in Cellular Neuroscience (2022)
Year of Publication: 2022 🧠

Linjing Mu | Brain PET Imaging Award | Best Researcher Award

Posted on by ScienceFather

Dr. Linjing Mu | Brain PET Imaging Award | Best Researcher Award

Dr. Linjing Mu, ETH Zurich, Switzerland

🔬 Dr. Linjing Mu pursued doctoral research at Nankai University, followed by a post-doctoral fellowship at Basel University, Switzerland. With expertise in radiopharmaceutical sciences, Dr. Mu led research teams at University Hospital Zurich and ETH Zurich, focusing on lead structure discovery, ligand synthesis, and radiolabeling method development. A prolific author, Dr. Mu has 106 peer-reviewed publications, including 10 as last and corresponding author, and 19 as the first author. Co-investigator on 10 patents, Dr. Mu has presented internationally and collaborated with industry leaders like Bayer Schering, Novartis, and Roche, contributing significantly to drug discovery and clinical translations.

 

Publication Profile:

Scopus

Orcid

Education:

Doctoral Research in Chemistry Department, Nankai University (1993-1996)

Post-Doctoral Fellow, Basel University, Switzerland (1996-2001)

Experience:

Team Leader in the field of Radiopharmaceutical Sciences, Group of Prof. Schubiger (2001-2010)

Head of Research, Radiopharmacy, University Hospital Zurich (2010-2021)

Senior Scientist, Prof. Schibli’s Group, ETH Zurich (2021-Present)

Research Expertise:

Lead Structure Finding based on Literature and Patents

Design and Synthesis of Novel Ligands

Structure-Activity Relationship Studies

Radiolabeling Method Development

In Vitro and In Vivo Evaluation

Academic Achievements:

Co-authored 106 Peer-Reviewed Publications

Last and Corresponding Author on 10, First Author on 19 (H-Factor 29, Scopus)

Co-Investigator on 10 Patent Applications

Contributed to International Conferences as Invited Speaker, Oral and Poster Presenter

Research Focus:

🔬 Dr. Linjing Mu’s research focus lies at the intersection of neuroimaging and drug development, particularly in the field of molecular imaging for neurodegenerative diseases like Alzheimer’s. Their work encompasses the development and optimization of radioligands targeting specific molecular pathways implicated in neurodegeneration. Through PET/MRI studies and the exploration of novel PET tracers, such as (R)-[18F]YH134 and (R)-[18F]PSS232, Dr. Mu aims to deepen our understanding of disease mechanisms and identify potential therapeutic targets. This research not only sheds light on disease pathology but also paves the way for the development of new diagnostic tools and pharmacological interventions.

 

Publication Top Notes:

📄 Wang, J. et al. Metabotropic glutamate receptor 5 (mGluR5) is associated with neurodegeneration and amyloid deposition in Alzheimer’s disease: A [18F]PSS232 PET/MRI study. Published in Alzheimer’s Research and Therapy, 2024. Cited by: 0.

📄 He, Y. et al. Identification of (R)-[18F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development. Published in Journal of Nuclear Medicine, 2024. Cited by: 0.

📄 Boccalini, C. et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Published in Alzheimer’s and Dementia, 2024. Cited by: 1.

📄 Trachsel, B. et al. Reducing kidney uptake of radiolabelled exendin-4 using variants of the renally cleavable linker MVK. Published in EJNMMI Radiopharmacy and Chemistry, 2023. Cited by: 0.

📄 Lu, Y. et al. Proof-of-concept optimization of a copper-mediated 18F-radiosynthesis of a novel MAGL PET tracer on a high-throughput microdroplet platform and its macroscale translation. Published in Lab on a Chip, 2023. Cited by: 1.

📄 Ni, R. et al. Imaging increased metabolism in the spinal cord in mice after middle cerebral artery occlusion. Published in Photoacoustics, 2023. Cited by: 0.

📄 Zechner, M. et al. In Vitro and In Vivo Evaluation of ABCG2 (BCRP) Inhibitors Derived from Ko143. Published in Journal of Medicinal Chemistry, 2023. Cited by: 1.

📄 Bengs, S. et al. Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice. Published in Journal of Nuclear Cardiology, 2023. Cited by: 3.

📄 Peretti, D.E. et al. ATN profile classification across two independent prospective cohorts. Published in Frontiers in Medicine, 2023. Cited by: 0.

📄 He, Y. et al. Multi-parameter optimization: Development of a morpholin-3-one derivative with an improved kinetic profile for imaging monoacylglycerol lipase in the brain. Published in European Journal of Medicinal Chemistry, 2022. Cited by: 2.